Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis

Braza-Boïls, Aitana; Salloum-Asfar, Salam; Marí-Alexandre, Josep; Arroyo, Ana B.; Gónzález-Conejero, Rocío; Barceló-Molina, Moisés; García-Oms, Javier; Vicente, Vicente; Estellés, Amparo; Gilabert-Estellés, Juan; Martı́nez, Constantino

doi:10.1093/humrep/dev204

Cited by 53 publications

(40 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, miR-424 decreases angiogenesis by directly reducing VEGFA protein levels in endometrial and endometriotic cells. 140 In keeping with this, miR-424 reduces cell proliferation and angiogenesis in senile haemangioma by inhibiting the expression of MEK1 and cyclin E1. 141 Interestingly, MEK1 and cyclin E1 may remain with the same signalling pathway to manage the cell cycle, because MEK1 is the upstream molecule of ERK and cyclin E1 is a downstream target of ERK.…”

mentioning

confidence: 76%

The regulatory role of microRNAs in angiogenesis‐related diseases

Sun

Lei

et al. 2018

J Cellular Molecular Medi

116

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non‐coding RNAs that regulate gene expression at a post‐transcriptional level via either the degradation or translational repression of a target mRNA. They play an irreplaceable role in angiogenesis by regulating the proliferation, differentiation, apoptosis, migration and tube formation of angiogenesis‐related cells, which are indispensable for multitudinous physiological and pathological processes, especially for the occurrence and development of vascular diseases. Imbalance between the regulation of miRNAs and angiogenesis may cause many diseases such as cancer, cardiovascular disease, aneurysm, Kawasaki disease, aortic dissection, phlebothrombosis and diabetic microvascular complication. Therefore, it is important to explore the essential role of miRNAs in angiogenesis, which might help to uncover new and effective therapeutic strategies for vascular diseases. This review focuses on the interactions between miRNAs and angiogenesis, and miRNA‐based biomarkers in the diagnosis, treatment and prognosis of angiogenesis‐related diseases, providing an update on the understanding of the clinical value of miRNAs in targeting angiogenesis.

show abstract

mentioning

confidence: 76%

The regulatory role of microRNAs in angiogenesis‐related diseases

Sun

Lei

et al. 2018

J Cellular Molecular Medi

116

View full text Add to dashboard Cite

show abstract

“…An emerging field in endometriosis is the function of miRNA in angiogenesis. Primary eutopic and ectopic endometrial stromal cells exposed to PF from women with endometriosis have downregulated miRNAs known to regulate VEGF expression compared to cells exposed to PF from control women (Braza-Boils et al 2013, Braza-Boils et al 2014, Braza-Boils et al 2015). Future in-depth analysis of the interplay between inflammation and angiogenesis in the early stages of endometriosis development is needed to determine which molecules could potentially be targeted therapeutically.…”

Section: Pathogenesis and Progression Of Endometriosismentioning

confidence: 95%

Endometriosis: where are we and where are we going?

Greene¹,

Lang²,

Kendziorski³

et al. 2016

Reproduction

142

113

View full text Add to dashboard Cite

Endometriosis currently affects ∼5.5 million reproductive-aged women in the U.S. with symptoms such as painful periods (dysmenorrhea), chronic pelvic pain, pain with intercourse (dyspareunia), and infertility. It is defined as the presence of endometrial tissue outside the uterine cavity and is found predominately attached to sites within the peritoneal cavity. Diagnosis for endometriosis is solely made through surgery as no consistent biomarkers for disease diagnosis exist. There is no cure for endometriosis and treatments only target symptoms and not the underlying mechanism(s) of disease. The nature of individual predisposing factors or inherent defects in the endometrium, immune system, and/or peritoneal cavity of women with endometriosis remains unclear. The literature over the last 5 years (2010-2015) has advanced our critical knowledge related to hormones, hormone receptors, immune dysregulation, hormonal treatments, and the transformation of endometriosis to ovarian cancer. In this review, we cover the aforementioned topics with the goal of providing the reader an overview and related references for further study to highlight the progress made in endometriosis research, while concluding with critical areas of endometriosis research that are urgently needed.

show abstract

“…Several putative regulators of PTEN have been reported, including caveolin‐1, DJ‐1, and miR‐21 . Remarkably, lower expression of caveolin‐1 has been reported in adenomyosis, and higher expression of DJ‐1 and miR‐21 has been reported in endometriosis as well. Inactivation of FOXO3a by SGK1 and ERβ also has been reported in endometriosis .…”

Section: Mutations Of Cancer Driver Genes In Endometriosis and Their mentioning

confidence: 99%

Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis

Guo

2018

Reprod Medicine & Biology

View full text Add to dashboard Cite

BackgroundOne recent study reports cancer driver mutations in deep endometriosis, but its biological/clinical significance remains unclear. Since the natural history of endometriosis is essentially gradual progression toward fibrosis, it is thus hypothesized that the six driver genes reported to be mutated in endometriosis (the RP set) may play important roles in fibrogenesis but not necessarily malignant transformation.MethodsExtensive PubMed search to see whether RP and another set of driver genes not yet reported (NR) to be mutated in endometriosis have any roles in fibrogenesis. All studies reporting on the role of fibrogenesis of the genes in both RP and NR sets were retrieved and evaluated in this review.ResultsAll six RP genes were involved in various aspects of fibrogenesis as compared with only three NR genes. These nine genes can be anchored in networks linking with their upstream and downstream genes that are known to be aberrantly expressed in endometriosis, piecing together seemingly unrelated findings.ConclusionsGiven that somatic driver mutations can and do occur frequently in physiologically normal tissues, it is argued that these mutations in endometriosis are not necessarily synonymous with malignancy or premalignancy, but the result of enormous pressure for fibrogenesis.

show abstract

Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis

Abstract: This work was supported by research grants by ISCIII and FEDER (PI11/00091, PI11/00566, PI14/01309, PI14/00253 and FI12/00012), RIC (RD12/0042/0029 and RD12/0042/0050), IIS La Fe 2011-211, Prometeo 2011/027 and Contrato Sara Borrell CD13/0005. There are no conflicts of interest to declare.

Cited by 53 publications

References 45 publications

The regulatory role of microRNAs in angiogenesis‐related diseases

The regulatory role of microRNAs in angiogenesis‐related diseases

Endometriosis: where are we and where are we going?

Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis

Contact Info

Product

Resources

About